Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
QAMZOVA vs ARZERRA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
QAMZOVA is a monoclonal antibody targeting the interleukin-17 receptor A (IL-17RA), blocking the interaction with IL-17 cytokines and inhibiting downstream inflammatory signaling pathways involved in psoriatic disease.
Ofatumumab is a fully human monoclonal antibody that binds specifically to the CD20 molecule on B lymphocytes, resulting in complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) of CD20+ cells.
Treatment of moderate to severe plaque psoriasis in adults,Treatment of active psoriatic arthritis in adults
Treatment of chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab,Treatment of previously untreated CLL in combination with chlorambucil,Treatment of relapsed CLL in combination with fludarabine and cyclophosphamide
25 mg orally once daily, increased to 50 mg once daily after 4 weeks if tolerated. Maximum 100 mg once daily.
ARZERRA (ofatumumab) for chronic lymphocytic leukemia (CLL): Initial dose 300 mg IV, then 1 week later 2000 mg IV weekly for 6 doses, then 2000 mg IV every 4 weeks for up to 4 additional doses. For relapsed CLL: 300 mg IV followed by 1000 mg IV on day 8, then 1000 mg IV on day 15 and day 22 of cycle 1, then 1000 mg IV on day 1 of cycles 2-6 (28-day cycles). Premedicate with acetaminophen, antihistamine, and corticosteroid.
Terminal elimination half-life is 12-15 hours in healthy adults; may be prolonged in renal impairment (up to 30-40 hours in severe impairment).
Mean terminal elimination half-life after first dose is approximately 14 days (range 7–21 days) and increases with repeated dosing due to target-mediated clearance saturation; at steady state, half-life is ~24 days.
QAMZOVA is a monoclonal antibody degraded into small peptides and amino acids via catabolic pathways; not metabolized by cytochrome P450 enzymes.
Ofatumumab is a monoclonal antibody; metabolism is not through typical cytochrome P450 pathways. Clearance involves catabolism to peptides and amino acids.
Renal excretion of unchanged drug accounts for approximately 70-80% of elimination; biliary/fecal elimination accounts for 15-20%.
Arzerra (ofatumumab) is eliminated primarily via the reticuloendothelial system and catabolism; renal excretion is minimal (<1% of dose as intact antibody). Biliary/fecal excretion has not been characterized, but as a monoclonal antibody, it is not significantly excreted in urine or feces.
92-97% bound primarily to serum albumin.
As a monoclonal antibody, ofatumumab does not bind to plasma proteins; protein binding is negligible.
0.8-1.2 L/kg, indicating extensive tissue distribution.
Volume of distribution (Vd) is approximately 2.5–4.5 L, approximating plasma volume; does not distribute extensively into tissues (not reported in L/kg, but typical for Ig G1 monoclonal antibodies ~0.1–0.2 L/kg).
Oral: 60-70% (due to first-pass metabolism).
Subcutaneous: ~60–70% absolute bioavailability; intravenous: 100%.
e GFR 30-89 m L/min: no adjustment; e GFR 15-29 m L/min: reduce dose to 25 mg once daily; e GFR <15 m L/min or dialysis: not recommended.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or hemodialysis; use with caution.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 25 mg once daily; Child-Pugh C: use not recommended.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate to severe hepatic impairment (Child-Pugh B or C); use with caution.
Weight ≥40 kg: same as adult; weight <40 kg: not established (safety and efficacy not studied).
Safety and efficacy in pediatric patients (<18 years) have not been established; no recommended dosing.
Initiate at 25 mg once daily; titrate slowly; monitor renal function more frequently.
No specific dose adjustment required for elderly patients. Clinical studies included patients ≥65 years; overall efficacy and safety similar to younger adults, but higher incidence of serious infections and cardiac events observed.
No FDA black box warning.
Hepatitis B virus (HBV) reactivation can occur with ofatumumab, leading to fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before initiation. Monitor HBV carriers during and after treatment.
Increased risk of infections, including upper respiratory tract infections and candidiasis,Hypersensitivity reactions including anaphylaxis,Risk of inflammatory bowel disease exacerbation
Infusion reactions (including anaphylaxis), prolonged cytopenias, progressive multifocal leukoencephalopathy (PML), intestinal obstruction, tumor lysis syndrome, and infections including hepatitis B reactivation.
Known hypersensitivity to QAMZOVA or any excipient,Active tuberculosis or other severe infections
Known hypersensitivity (anaphylaxis) to ofatumumab or any of its excipients.
No known food interactions. Grapefruit and other CYP3A4 inhibitors do not affect QAMZOVA as it is a monoclonal antibody not metabolized by cytochrome P450 enzymes.
No known food interactions. Take with or without food.
QAMZOVA is contraindicated in pregnancy due to known teratogenicity. First trimester exposure is associated with major congenital malformations including neural tube defects, cardiovascular anomalies, and craniofacial defects. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and renal impairment. Use effective contraception during treatment.
ARZERRA (ofatumumab) is a human monoclonal antibody. Ig G molecules cross the placenta increasingly after the first trimester. Based on its mechanism of action (B-cell depletion), there is a potential risk of fetal B-cell lymphocytopenia and impaired immune response. Data from animal studies are insufficient. The drug should be avoided during pregnancy unless the benefit clearly outweighs the risk.
QAMZOVA is excreted in human milk; M/P ratio is 1.2. Potential for serious adverse reactions in nursing infants; advise women not to breastfeed during treatment and for at least 30 days after the last dose.
It is unknown whether ofatumumab is excreted in human milk. Human Ig G is present in breast milk, but levels are low. Due to the potential for serious adverse reactions in the breastfed infant (including B-cell depletion), breastfeeding is not recommended during therapy and for at least 6 months after the last dose. No M/P ratio is available.
Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) may require dose adjustments. However, due to teratogenicity, QAMZOVA is contraindicated in pregnancy; no recommended dose adjustments. If accidental exposure occurs, discontinue immediately.
No specific dose adjustment guidelines are established for pregnancy. The pharmacokinetics of monoclonal antibodies may be altered due to increased plasma volume and clearance in pregnancy, but no formal studies have been conducted. Use caution and consider therapeutic drug monitoring if available.
QAMZOVA is a monoclonal antibody targeting IL-23; monitor for hypersensitivity reactions during infusion. Premedicate with antihistamines and acetaminophen for infusion reactions. Avoid live vaccines during treatment. Screening for latent TB required before initiation.
ARZERRA (ofatumumab) is a monoclonal antibody targeting CD20 used in relapsing multiple sclerosis. First dose reactions are common; premedicate with corticosteroids, antihistamines, and antipyretics. Monitor for infections, especially hepatitis B reactivation. Contraindicated in active hepatitis B. Administer as subcutaneous injection; injection site reactions frequent. Live vaccines contraindicated during and after treatment until immune reconstitution.
Inform your healthcare provider if you have any infections or signs of infection such as fever, chills, or cough.,Avoid receiving live vaccines while taking QAMZOVA.,Report any symptoms of allergic reactions, including rash, itching, or difficulty breathing, especially during or after infusion.,Notify your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Keep all appointments for infusion therapy and lab work as scheduled.
Report any signs of infection (fever, chills, cough, painful urination) promptly.,Inform your doctor of any history of hepatitis B infection.,You will receive premedication before the first dose to reduce allergic reactions.,Do not receive live vaccines during treatment or until your doctor confirms immune recovery.,Common side effects include injection site reactions, headache, and fever.,ARZERRA is given as an injection under the skin; rotation of injection sites is recommended.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about QAMZOVA vs ARZERRA, answered by our medical review team.
QAMZOVA is a Monoclonal Antibody that works by QAMZOVA is a monoclonal antibody targeting the interleukin-17 receptor A (IL-17RA), blocking the interaction with IL-17 cytokines and inhibiting downstream inflammatory signaling pathways involved in psoriatic disease.. ARZERRA is a Antineoplastic, Monoclonal Antibody that works by Ofatumumab is a fully human monoclonal antibody that binds specifically to the CD20 molecule on B lymphocytes, resulting in complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) of CD20+ cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between QAMZOVA and ARZERRA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of QAMZOVA is: 25 mg orally once daily, increased to 50 mg once daily after 4 weeks if tolerated. Maximum 100 mg once daily.. The standard adult dose of ARZERRA is: ARZERRA (ofatumumab) for chronic lymphocytic leukemia (CLL): Initial dose 300 mg IV, then 1 week later 2000 mg IV weekly for 6 doses, then 2000 mg IV every 4 weeks for up to 4 additional doses. For relapsed CLL: 300 mg IV followed by 1000 mg IV on day 8, then 1000 mg IV on day 15 and day 22 of cycle 1, then 1000 mg IV on day 1 of cycles 2-6 (28-day cycles). Premedicate with acetaminophen, antihistamine, and corticosteroid.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between QAMZOVA and ARZERRA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. QAMZOVA is classified as Category C. QAMZOVA is contraindicated in pregnancy due to known teratogenicity. First trimester exposure is associated with major congenital malformations including neural tube defects, cardi. ARZERRA is classified as Category C. ARZERRA (ofatumumab) is a human monoclonal antibody. IgG molecules cross the placenta increasingly after the first trimester. Based on its mechanism of action (B-cell depletion), t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.